Seattle Genetics, the Bothell, WA-based developer of targeted antibody drugs, has raised another $11.5 million, according to a regulatory filing. The company received approval from existing shareholders sell more shares to Baker Brothers Life Sciences, an investment firm led by one of the firm’s directors, Felix Baker. The $11.5 million sale was a follow-on transaction from a $55 million offering the company pulled together in January.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
